Vertex Pharmaceuticals Incorporated
VRTX
#161
Rank
$138.717 B
Marketcap
United States
Country
$547.29
Share price
3.33%
Change (1 day)
33.97%
Change (1 year)
Categories
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one…
Key Metrics
Trailing P/E
29.85
Forward P/E
25.65
EPS (TTM)
$17.30
Forward EPS
$20.13
Price / Book
6.46
EV / EBITDA
24.5x
Beta
0.32
Dividend Yield
—
Return on Equity
23.54%
Return on Assets
11.93%
Debt / Equity
9.77
Current Ratio
3.19
Gross Margin
54.96%
Operating Margin
38.05%
Net Profit Margin
35.00%
Free Cash Flow
$2.628B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 17
-6.47%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$12.001B
Latest Net Income$3.953B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Vertex Pharmaceuticals Incorporated with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
VRTX
No recent news available. Set FINNHUB_API_KEY to enable news.
